Aprexis, Inc. — SEC Form D Filing

Aprexis, Inc. filed an SEC Form D on November 10, 2026, reporting $2.22M raised in Healthtech.

Form D filing details

Filing
SEC Form D
Filing date
November 10, 2026
Amount reported
$2.22M
Industry
Healthtech
Website
https://aprexis.com/

What the company does

Securities: Debt. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Health plan pharmacy teams face rising complexity and limited resources while under pressure to reduce avoidable medical and pharmacy spend, meet Star Ratings and HEDIS quality targets, and ensure members properly take and adhere to medications after they are prescribed.

Solution

Aprexis provides a pharmacy care management platform available as a SaaS tool or fully delegated clinical service to help Medicare, Medicaid, and Commercial health plans improve medication adherence, close care gaps, and optimize pharmacy spending.

Why now

CMS has increased the weight and financial implications of medication adherence and quality measures in Medicare Advantage Star ratings, compelling plans to actively manage member drug therapies.

Verdict

Investors backed this sub-scale round because shifting CMS Star Ratings directly tied medication adherence to Medicare Advantage bonus pools, giving regional health plans an immediate, board-level ROI justification for niche clinical intervention workflows. They were implicitly betting that mid-tier plans would bypass monolithic PBM tools in favor of specialized, plug-and-play pharmacy care workflows. This cleared because quality measure penalties made health plan inaction financially untenable, not because Aprexis demonstrated a proprietary technology moat over incumbent vendors. Ultimate upside remains capped by slow enterprise payer sales cycles and the margin drag inherent in offering delegated clinical services.

Source: SEC EDGAR Form D filing